{"filing":{"accession_number":"0001193125-26-428938","cik":"0001503802","ticker":"KPTI","company_name":"Karyopharm Therapeutics Inc.","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-22","primary_document":"d172630d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526428938/d172630d8k.htm"},"events":[{"id":37249,"run_id":34340,"accession_number":"0001193125-26-428938","anchor_item_number":"8.01","event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"The filing discloses a Forbearance Agreement and Limited Waiver to Indentures dated September 10, 2026, with successive extensions of the forbearance period through November 1, 2026. A forbearance agreement is a creditor's agreement to temporarily waive enforcement of debt covenants or defaults, indicating the company has triggered or is at risk of triggering a covenant breach or technical default. The repeated extensions signal ongoing financial stress and a direct obligation to cure or negotiate with debt holders.","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":41902,"accession_number":"0001193125-26-428938","item_number":"8.01","item_title":null,"event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a Forbearance Agreement and Limited Waiver to Indentures dated September 10, 2026, with successive extensions of the forbearance period through November 1, 2026. A forbearance agreement is a creditor's agreement to temporarily waive enforcement of debt covenants or defaults, indicating the company has triggered or is at risk of triggering a covenant breach or technical default. The repeated extensions signal ongoing financial stress and a direct obligation to cure or negotiate with debt holders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T20:17:15.058832+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41902,"accession_number":"0001193125-26-428938","item_number":"8.01","item_title":null,"event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a Forbearance Agreement and Limited Waiver to Indentures dated September 10, 2026, with successive extensions of the forbearance period through November 1, 2026. A forbearance agreement is a creditor's agreement to temporarily waive enforcement of debt covenants or defaults, indicating the company has triggered or is at risk of triggering a covenant breach or technical default. The repeated extensions signal ongoing financial stress and a direct obligation to cure or negotiate with debt holders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T20:17:15.058832+00:00","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-10-22"}]}